Get 40% Off
🤑 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

China's slow approvals of biotech crops cost U.S. $7 billion, says industry group

Published 30/05/2018, 12:10
© Reuters. FILE PHOTO: Genetically modified corn are seen cultivated at a greenhouse in Syngenta Biotech Center in Beijing
BAYGN
-
DD
-
MON
-

By Tom Polansek

CHICAGO (Reuters) - Delays in Chinese approvals of imported genetically modified crops have cut U.S. gross domestic product by about $7 billion (5.3 billion pounds) over the past five years by reducing sales of crops and other goods, an industry group that represents global seed companies said on Wednesday.

The report by CropLife International indicates what is at stake for the administration of President Donald Trump as it seeks better access for U.S. GMO crops into China as part of a trade deal under discussion.

U.S. Commerce Secretary Wilbur Ross is set to visit Beijing this week for talks, after months of escalating tensions that had threatened a trade war.

The United States said on Tuesday it still held its threat of imposing tariffs on $50 billion of imports from China and would use it unless Beijing addressed its concerns over the theft of American intellectual property.

Global seeds and chemical companies have long wanted wider access for GMO crops in China because it is the world's top buyer of soybeans and a major buyer of other grains.

China does not permit planting of GMO food crops but allows imports of GMO soybeans and corn for use in its massive animal feed industry. But the approval process for new GMO strains is slow, unpredictable and not based on science, according to the U.S. biotech industry.

The sector says delays in Chinese approvals hurt the value of U.S. corn harvests by preventing farmers from using new seeds that can protect crops from pests and weeds.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

As a result, farmers spend less on products ranging from fertilizer to equipment, with ripple effects on economic growth, said Scott Richman, senior vice president at Informa Agribusiness Consulting Group, which CropLife commissioned to do the study.

China's Ministry of Agriculture and Rural Affairs, which regulates GMO crop approvals, did not respond to a fax seeking comment on how its reviews affect the U.S. economy.

"We need a system in China that facilitates trade," said Matt O'Mara, a vice president for the Biotechnology Innovation Organization, a CropLife affiliate.

Companies such as Bayer AG (DE:BAYGn), Monsanto Co (N:MON), DowDuPont (N:DWDP) and ChemChina's Syngenta have been waiting as long as seven years for China to approve strains of soybeans, canola and alfalfa.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.